Skip to content
Markets News
Stocks2 min read

Scholar Rock Clears FDA Hurdle With First Muscle-Targeted SMA Drug

Makkler Newsroom
September 15, 2026 · Based on reporting by InvestorsHub

ISEMBYLD approval moves Scholar Rock into commercialization after a manufacturing setback delayed its first attempt last year.

Scholar Rock shares climbed 9.1% to $60.45 in premarket trading Monday after the FDA approved ISEMBYLD, giving the biotechnology company its first commercial product and clearing a regulatory obstacle that had shadowed the stock for a year.

The approval, announced Friday, September 11, arrived ahead of the agency’s September 30 action deadline. It covers adults and children at least 2 years old with spinal muscular atrophy who are already receiving an SMN2-targeted treatment, including therapies such as Spinraza and Evrysdi that help preserve motor neurons.

ISEMBYLD, or apitegromab-mstn, takes a different approach. It inhibits myostatin, a protein that restrains muscle growth, aiming to address the muscle wasting that can continue even when SMN2-directed medicines slow the underlying nerve damage. The FDA described it as the first approved SMA therapy to directly target muscle loss.

The decision rested on Scholar Rock’s 52-week SAPPHIRE trial, in which all participants received background SMN2 therapy. Among patients aged 2 to 12, the recommended 10-milligram-per-kilogram dose produced a 2.2-point improvement over placebo on the Hammersmith Functional Motor Scale-Expanded. A clinically meaningful improvement of at least three points occurred in 34.2% of treated patients, compared with 13.5% on placebo.

That efficacy profile now faces the harder commercial test. Scholar Rock said product shipments would begin within days, while management told investors Monday that the annual list price for a typical patient would be about $310,000. Coverage decisions, infusion-center logistics and the need for combination treatment will shape how quickly physicians adopt the drug.

Manufacturing had already forced the company to navigate a difficult path. The FDA rejected the original application in September 2025 after raising concerns at a fill-finish facility formerly operated by Catalent and now owned by Novo Nordisk. Scholar Rock later removed that site from its filing and advanced a second U.S. facility, reducing the supply risk before this year’s approval.

The company also received a rare pediatric disease priority review voucher, an asset that may accelerate a future application or carry financial value if transferred. For investors, the FDA action converts Scholar Rock from a clinical-stage biotech into a launch-stage drugmaker. Execution now matters as much as science.

Topics
SRRKISEMBYLDScholar RockApitegromab
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.